OKYO Pharma Limited
OKYO
$2.42
$0.052.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 10.17% | 10.17% | -72.83% | -72.83% | -14.48% |
| Gross Profit | -10.17% | -10.17% | 72.83% | 72.83% | 14.48% |
| SG&A Expenses | -- | -- | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -46.51% | -46.51% | -61.77% | -61.77% | -8.87% |
| Operating Income | 46.51% | 46.51% | 61.77% | 61.77% | 8.87% |
| Income Before Tax | 52.01% | 52.01% | 53.09% | 53.09% | -3.51% |
| Income Tax Expenses | -2,956.29% | -2,956.29% | -1,812.32% | -1,812.32% | -395.08% |
| Earnings from Continuing Operations | 74.70% | 74.70% | 69.61% | 69.61% | -2.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 74.70% | 74.70% | 69.61% | 69.61% | -2.89% |
| EBIT | 46.51% | 46.51% | 61.77% | 61.77% | 8.87% |
| EBITDA | 46.51% | 46.51% | 61.78% | 61.78% | 8.87% |
| EPS Basic | 81.63% | 81.63% | 76.73% | 76.73% | 28.63% |
| Normalized Basic EPS | 65.10% | 65.10% | 64.09% | 64.09% | 28.17% |
| EPS Diluted | 81.63% | 81.63% | 76.73% | 76.73% | 28.63% |
| Normalized Diluted EPS | 65.10% | 65.10% | 64.09% | 64.09% | 28.17% |
| Average Basic Shares Outstanding | 37.70% | 37.70% | 30.56% | 30.56% | 44.17% |
| Average Diluted Shares Outstanding | 37.70% | 37.70% | 30.56% | 30.56% | 44.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |